Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IlluminaXSWX:ILMN 76 Cash-to-Debt is 0.46 as of Jun. 2026, which is 51% below its 10-year median of 0.93. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF107.32. The stock has 7 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Illumina ranks worse than 68.57% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Illumina's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.46.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Illuminacouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Illumina's Cash-to-Debt or its related term are showing as below:
XSWX:ILMN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.34 Med: 0.93 Max: 1.84
Current: 0.46
During the past 13 years, Illumina's highest Cash to Debt Ratio was 1.84. The lowest was 0.34. And the median was 0.93.
XSWX:ILMN's Cash-to-Debt is ranked worse than 68.57% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.055
vs XSWX:ILMN: 0.46
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Illumina Cash-to-Debt Related Terms
Illumina Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Illumina's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:ILMN vs MTD, DGX, LH: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Illumina's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Illumina's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XSWX:ILMN) has a Cash-to-Debt of 0.46 as of Jun. 2026. This is 51% below median its historical median of 0.93. Over the past decade, Illumina's Cash-to-Debt has ranged from 0.34 to 1.84. According to the industry distribution chart, Illumina ranks #144 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 68.6%.
Is Illumina's Cash-to-Debt too high?
Illumina's current Cash-to-Debt of 0.46 is 51% below median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 1.84. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.06. Illumina's value of 0.46 is 56.4% below this industry median. Based on the distribution chart, Illumina ranks #144 out of 210 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Cash-to-Debt compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #144 out of 210 companies for Cash-to-Debt. This places Illumina in the lower half of its industry. The industry median Cash-to-Debt is 1.06. Illumina's value of 0.46 is 56.4% below this benchmark. Historically, Illumina's own Cash-to-Debt has ranged from 0.34 to 1.84 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 1.06, Illumina has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.06, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current Cash-to-Debt of 0.46 is 56.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Cash-to-Debt is 0.46, which is 51% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Cash-to-Debt of 0.46. The stock's GF Value™ is CHF107.32, compared to a current price of CHF155.14 — trading 44.6% above its estimated fair value. The current Cash-to-Debt is 0.46, which is 51% below median its 10-year median of 0.93 and 56.4% below the Medical Diagnostics & Research industry median of 1.06. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Cash-to-Debt is 0.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF155.14 is trading 44.6% above its estimated GF Value™ of CHF107.32.
Key valuation signals for XSWX:ILMN:
Cash-to-Debt: 0.46 (51% below median its 10-year median of 0.93)
GF Value™: CHF107.32 vs. price of CHF155.14 (44.6% above fair value)
Industry Position: 56.4% below the Medical Diagnostics & Research median (#144 of 210)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
